GILD

$170.683.06%5.07

Nachbörslich: 170.73+0.05 +0.03%

Gilead Sciences Inc (GILD)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$165.61

Offen:

$170.25

24-Stunden-Volumen:

11,287,113

Relatives Volumen:

1.69

Marktkapitalisierung:

$211.64B

Einnahmen:

$29.79B

Nettoeinkommen (Verlust:

$9.22B

KGV:

23.22

EPS:

$7.35

Netto-Cashflow:

$10.23B

1W Leistung:

+9.38%

1M Leistung:

+14.51%

6M Leistung:

+30.45%

1Y Leistung:

+44.11%

1-Tages-Spanne:

$169.00$175.65

1-Wochen-Bereich:

$155.76$175.65

52-Wochen-Spanne:

$114.02$175.65

Gilead Sciences Inc Aktie (GILD) Unternehmensprofil

Firmenname

Gilead Sciences Inc

Sektor

Healthcare

Branche

Drug Manufacturers - General

Telefon

(650) 574-3000

Adresse

333 LAKESIDE DR, FOSTER CITY, CA, USA

Mitarbeiter

17,000

@GileadSciences

Nächster Verdiensttermin

null

Neueste SEC-Einreichungen

SEC

GILD-Diskussionen auf X

GILD vs. LLY, JNJ, ABBV, MRK, NVS vergleichen

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GILD Gilead Sciences Inc	$170.68	$211.64B	$29.79B	$9.22B	$10.23B	$7.35
LLY Lilly Eli Co	$1,417.54	$1.26T	$72.25B	$25.28B	$10.37B	$27.78
JNJ Johnson Johnson	$273.20	$657.68B	$97.93B	$21.04B	$17.80B	$8.63
ABBV Abbvie Inc	$294.89	$521.11B	$62.82B	$3.60B	$19.98B	$2.03
MRK Merck Co Inc	$149.52	$368.89B	$65.51B	$8.93B	$14.12B	$3.55
NVS Novartis Ag Adr	$160.79	$303.67B	$54.66B	$13.58B	$16.05B	$7.02

Gilead Sciences Inc Aktie (GILD) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-07-21	Herabstufung	Leerink Partners	Outperform → Market Perform
2026-07-06	Hochstufung	HSBC Securities	Hold → Buy
2026-05-20	Hochstufung	Maxim Group	Hold → Buy
2026-03-10	Eingeleitet	Jefferies	Buy
2026-02-20	Eingeleitet	Barclays	Equal Weight
2026-02-11	Bestätigt	Needham	Buy
2026-01-07	Resumed	UBS	Buy
2025-11-24	Resumed	Truist	Buy
2025-11-13	Eingeleitet	Scotiabank	Sector Outperform
2025-08-19	Hochstufung	Daiwa Securities	Neutral → Outperform
2025-08-08	Hochstufung	Truist	Hold → Buy
2025-07-25	Hochstufung	Needham	Hold → Buy
2025-04-22	Resumed	Cantor Fitzgerald	Overweight
2025-03-04	Bestätigt	Oppenheimer	Outperform
2025-02-18	Hochstufung	Deutsche Bank	Hold → Buy
2025-02-13	Hochstufung	DZ Bank	Hold → Buy
2025-01-10	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	Resumed	BofA Securities	Buy
2024-11-15	Eingeleitet	Wolfe Research	Outperform
2024-11-14	Eingeleitet	Citigroup	Buy
2024-11-08	Herabstufung	Maxim Group	Buy → Hold
2024-10-21	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-10-17	Eingeleitet	Bernstein	Outperform
2024-10-07	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-07-08	Hochstufung	Raymond James	Mkt Perform → Outperform
2024-05-01	Bestätigt	Maxim Group	Buy
2024-04-24	Hochstufung	HSBC Securities	Reduce → Hold
2024-02-22	Herabstufung	Truist	Buy → Hold
2023-11-09	Eingeleitet	Deutsche Bank	Hold
2023-09-08	Hochstufung	BofA Securities	Neutral → Buy
2023-09-06	Eingeleitet	HSBC Securities	Reduce
2023-07-24	Bestätigt	Barclays	Equal Weight
2023-05-16	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2023-04-28	Resumed	Piper Sandler	Overweight
2023-01-03	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	Resumed	BofA Securities	Neutral
2022-12-09	Herabstufung	DZ Bank	Buy → Hold
2022-10-31	Hochstufung	Barclays	Underweight → Equal Weight
2022-10-28	Bestätigt	BMO Capital Markets	Market Perform
2022-10-28	Bestätigt	Cowen	Outperform
2022-10-28	Bestätigt	JP Morgan	Overweight
2022-10-28	Bestätigt	Jefferies	Buy
2022-10-28	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-28	Bestätigt	RBC Capital Mkts	Outperform
2022-10-28	Hochstufung	Truist	Hold → Buy
2022-10-28	Bestätigt	Wells Fargo	Equal Weight
2022-10-04	Hochstufung	JP Morgan	Neutral → Overweight
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-05-23	Eingeleitet	SVB Leerink	Mkt Perform
2022-02-28	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2022-02-02	Bestätigt	BMO Capital Markets	Outperform
2022-02-02	Bestätigt	BofA Securities	Neutral
2022-02-02	Bestätigt	RBC Capital Mkts	Outperform
2022-02-02	Bestätigt	Truist	Hold
2022-02-02	Bestätigt	Wells Fargo	Equal Weight
2022-01-28	Hochstufung	Argus	Hold → Buy
2022-01-06	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	Resumed	Wells Fargo	Equal Weight
2021-12-06	Eingeleitet	Goldman	Neutral
2021-11-19	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-11-19	Resumed	Piper Sandler	Neutral
2021-10-20	Resumed	Cowen	Outperform
2021-07-30	Bestätigt	BMO Capital Markets	Market Perform
2021-07-30	Bestätigt	RBC Capital Mkts	Outperform
2021-04-01	Hochstufung	Bernstein	Mkt Perform → Outperform
2021-03-30	Hochstufung	Redburn	Neutral → Buy
2021-01-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	Hochstufung	Guggenheim	Neutral → Buy
2020-11-03	Resumed	Morgan Stanley	Equal-Weight
2020-10-28	Eingeleitet	UBS	Neutral
2020-09-30	Resumed	Jefferies	Buy
2020-09-15	Hochstufung	Maxim Group	Hold → Buy
2020-07-31	Bestätigt	Credit Suisse	Neutral
2020-07-31	Bestätigt	Morgan Stanley	Equal-Weight
2020-07-31	Bestätigt	Piper Sandler	Overweight
2020-07-31	Bestätigt	RBC Capital Mkts	Outperform
2020-07-31	Bestätigt	SunTrust	Hold
2020-07-31	Bestätigt	Wells Fargo	Equal Weight
2020-07-20	Hochstufung	Credit Suisse	Underperform → Neutral
2020-06-03	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2020-05-26	Hochstufung	SunTrust	Sell → Hold
2020-05-01	Herabstufung	JP Morgan	Overweight → Neutral
2020-05-01	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-05-01	Herabstufung	SunTrust	Hold → Sell
2020-04-27	Herabstufung	UBS	Buy → Neutral
2020-04-20	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2020-04-20	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-17	Herabstufung	CFRA	Hold → Sell

Finanzdaten der Gilead Sciences Inc-Aktie (GILD)

Umsatz

Nettogewinn

Free Cashflow

ENV

Gilead Sciences Inc-Aktie (GILD) Insiderhandel

Mercier JohannaOct 15 '26
Chief Comm & Corp Aff Officer
Transaktion
Sale
Kosten
$156.22
#Aktien
3,000
Wert ($)
468,660
#Aktien Gesamt
113,684
JOHANNA MERCIEROct 15 '26
Officer
Transaktion
Proposed Sale
Kosten
$156.22
#Aktien
3,000
Wert ($)
468,660
#Aktien Gesamt
0
Dickinson Andrew DOct 15 '26
Chief Financial Officer
Transaktion
Sale
Kosten
$156.22
#Aktien
3,000
Wert ($)
468,660
#Aktien Gesamt
161,096
ANDREW DICKINSONOct 15 '26
Officer
Transaktion
Proposed Sale
Kosten
$156.22
#Aktien
3,000
Wert ($)
468,660
#Aktien Gesamt
0
O'Day Daniel PatrickOct 01 '26
Chairman & CEO
Transaktion
Sale
Kosten
$147.90
#Aktien
15,000
Wert ($)
2,218,508
#Aktien Gesamt
566,683
ANDREW DICKINSONSep 15 '26
Officer
Transaktion
Proposed Sale
Kosten
$145.29
#Aktien
3,000
Wert ($)
435,870
#Aktien Gesamt
0
Mercier JohannaSep 15 '26
Chief Comm & Corp Aff Officer
Transaktion
Sale
Kosten
$144.22
#Aktien
3,000
Wert ($)
432,646
#Aktien Gesamt
116,684
Dickinson Andrew DSep 15 '26
Chief Financial Officer
Transaktion
Sale
Kosten
$145.29
#Aktien
3,000
Wert ($)
435,870
#Aktien Gesamt
164,096
JOHANNA MERCIERSep 15 '26
Officer
Transaktion
Proposed Sale
Kosten
$144.22
#Aktien
3,000
Wert ($)
432,646
#Aktien Gesamt
0
O'Day Daniel PatrickSep 01 '26
Chairman & CEO
Transaktion
Sale
Kosten
$148.64
#Aktien
15,000
Wert ($)
2,229,592
#Aktien Gesamt
577,133

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Mercier Johanna	Chief Comm & Corp Aff Officer	Oct 15 '26	Sale	$156.22	3,000	468,660	113,684
JOHANNA MERCIER	Officer	Oct 15 '26	Proposed Sale	$156.22	3,000	468,660	0
Dickinson Andrew D	Chief Financial Officer	Oct 15 '26	Sale	$156.22	3,000	468,660	161,096
ANDREW DICKINSON	Officer	Oct 15 '26	Proposed Sale	$156.22	3,000	468,660	0
O'Day Daniel Patrick	Chairman & CEO	Oct 01 '26	Sale	$147.90	15,000	2,218,508	566,683
ANDREW DICKINSON	Officer	Sep 15 '26	Proposed Sale	$145.29	3,000	435,870	0
Mercier Johanna	Chief Comm & Corp Aff Officer	Sep 15 '26	Sale	$144.22	3,000	432,646	116,684
Dickinson Andrew D	Chief Financial Officer	Sep 15 '26	Sale	$145.29	3,000	435,870	164,096
JOHANNA MERCIER	Officer	Sep 15 '26	Proposed Sale	$144.22	3,000	432,646	0
O'Day Daniel Patrick	Chairman & CEO	Sep 01 '26	Sale	$148.64	15,000	2,229,592	577,133

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

Oct 30, 2026

GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth - Zacks Investment Research

Oct 30, 2026

GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks - Zacks Investment Research

Oct 30, 2026

Gilead Sciences (GILD) Reports Strong Q3 2026 Sales Growth, Rais - GuruFocus

Oct 30, 2026

Gilead Sciences Inc (GILD) (Q3 2026) Earnings Call Highlights: Base Business Surges 16% as HIV ... - Yahoo Finance

Oct 30, 2026

Oct 29, 2026

What Gilead Sciences (GILD) Said on Its Q3 Earnings Call - Yahoo Finance

Oct 29, 2026

Gilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Zacks Investment Research

Oct 29, 2026

Gilead Sciences, Inc. (GIS.F) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Oct 29, 2026

Gilead Sciences, Inc. (GILD.VI) Seasonal returns chart - Yahoo Finance Australia

Oct 29, 2026

Gilead Sciences, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:GILD) 2026-10-29 - Seeking Alpha

Oct 29, 2026

Gilead Sciences, Inc. (GILD) Seasonal returns chart - Yahoo Finance UK

Oct 29, 2026

Gilead Sciences, Inc. (GILD.MX) Seasonal returns chart - Yahoo Finance Australia

Oct 29, 2026

Gilead Sciences, Inc. (GILD) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Oct 29, 2026

Gilead Sciences, Inc. reports results for the quarter ended September 30 - Earnings Summary - TradingView

Oct 29, 2026

Gilead Sciences Q3 2026 Earnings Call Transcript - Benzinga

Oct 29, 2026

How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade - Investor's Business Daily

Oct 29, 2026

A Look at Gilead Sciences Inc (GILD) After 4.0% Gain -- GF Value $107.30 vs Price $165.61 - GuruFocus

Oct 29, 2026

Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates - Yahoo Finance

Oct 29, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 29, 2026

Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength - WSJ

Oct 29, 2026

Gilead Sciences (NASDAQ:GILD) surprises with Q3 2026 sales, full-year outlook slightly exceeds expectations - Yahoo Finance

Oct 29, 2026

Gilead: Q3 Earnings Snapshot - Yahoo Finance

Oct 29, 2026

Gilead hikes full-year sales outlook, quarterly HIV sales rise 18% - Yahoo Finance

Oct 29, 2026

Breakfast News: Brace for an AI Optics Shake-up - The Motley Fool

Oct 29, 2026

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial - GlobeNewswire Inc.

Oct 29, 2026

Should You Invest in the iShares Biotechnology ETF (IBB)? - Zacks Investment Research

Oct 29, 2026

Oct 28, 2026

Gilead Sciences earnings: what to look for from GILD - Yahoo Finance

Oct 28, 2026

Oct 27, 2026

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool

Oct 27, 2026

Gilead to Report Q3 Earnings: How Should You Play the Stock Now? - Zacks Investment Research

Oct 27, 2026

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool

Oct 27, 2026

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - Zacks Investment Research

Oct 27, 2026

What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - Zacks Investment Research

Oct 27, 2026

Gilead Sciences, Inc. (GIS.F) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 27, 2026

Is Gilead Stock Increasing Your Market Risk? - Trefis

Oct 27, 2026

Oct 26, 2026

What Would A Biktarvy Slowdown Do To Gilead Stock? - Trefis

Oct 26, 2026

Gilead Sciences Q3 2026 Earnings Preview — October 29, Street Expects $2.21 EPS - AlphaStreet

Oct 26, 2026

BHC Q3 Earnings Preview: Here's What You Should Know - Zacks Investment Research

Oct 26, 2026

Gilead Sciences Q3 2026 Earnings Preview — October 29, Street Expects $2.21 EPS - AlphaStreet

Oct 26, 2026

Gilead's Latest Deal Shows Big Pharma's Appetite for Oral Peptides. Which Stocks Are Worth Watching? - Benzinga

Oct 26, 2026

Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? - The Motley Fool

Oct 26, 2026

TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research

Oct 26, 2026

Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance

Oct 26, 2026

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research

Oct 26, 2026

Gilead Sciences, Inc. $GILD Stock: Citizens Financial Group Inc. RI Increases Stake - MarketBeat

Oct 26, 2026

Oct 25, 2026

VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? - The Motley Fool

Oct 25, 2026

Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? - Yahoo Finance

Oct 25, 2026

Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? - The Motley Fool

Oct 25, 2026

Oct 24, 2026

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool

Oct 24, 2026

Oct 23, 2026

Gilead expands in I&I with $1.28B Pepstar deal for oral IL-23Ri - BioWorld News

Oct 23, 2026

Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche - Pharmaceutical Executive

Oct 23, 2026

Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar - BioSpace

Oct 23, 2026

Ähnlich wie GILD